Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.  

Starpharma today announced positive interim results from its ongoing phase 2 trial of DEP^® cabazitaxel, showing that 100% (22/22) of evaluable patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.

AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, showcasing AstraZeneca’s first DEP^® oncology product, AZD0466.

Starpharma today announced that it has been invited to present at the 11^th annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28‑29 October 2021.

Starpharma today notifies that the AGM of Starpharma Holdings Limited will be held as a virtual event at 11:00am (Melbourne time) on Tuesday, 30 November 2021.

Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP^® cabazitaxel.

Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 17 September 2020 (US ET) as part of OTCQX’s Life Sciences Investor Forum.

Starpharma today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.